These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 20199979

  • 21. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson PM, John W, Chouaki N, Visseren-Grul C, Paz-Ares LG.
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [Abstract] [Full Text] [Related]

  • 22. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.
    J Clin Oncol; 2009 Oct 01; 27(28):4787-92. PubMed ID: 19720897
    [Abstract] [Full Text] [Related]

  • 23. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
    Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS.
    Cancer; 2005 Dec 01; 104(11):2449-56. PubMed ID: 16258975
    [Abstract] [Full Text] [Related]

  • 24. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC.
    Clin Lung Cancer; 2009 Jul 01; 10(4):252-6. PubMed ID: 19632943
    [Abstract] [Full Text] [Related]

  • 25. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, Takeuchi Y, Kida H, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I.
    Lung Cancer; 2013 Nov 01; 82(2):271-5. PubMed ID: 23993733
    [Abstract] [Full Text] [Related]

  • 26. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK.
    J Clin Oncol; 2006 Oct 20; 24(30):4840-7. PubMed ID: 17050869
    [Abstract] [Full Text] [Related]

  • 27. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH, Gootenberg J, Keegan P, Pazdur R.
    Oncologist; 2007 Jun 20; 12(6):713-8. PubMed ID: 17602060
    [Abstract] [Full Text] [Related]

  • 28. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N.
    J Clin Oncol; 2010 Apr 10; 28(11):1835-42. PubMed ID: 20212250
    [Abstract] [Full Text] [Related]

  • 29. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.
    Health Technol Assess; 2010 Oct 10; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C, Wu Y, Sun Y, Wang Y, Wang X, Zhang X.
    Zhonghua Zhong Liu Za Zhi; 2014 Jan 10; 36(1):29-33. PubMed ID: 24685083
    [Abstract] [Full Text] [Related]

  • 32. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.
    J Thorac Oncol; 2013 Jul 10; 8(7):930-9. PubMed ID: 23722170
    [Abstract] [Full Text] [Related]

  • 33. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M.
    J Thorac Oncol; 2011 Nov 10; 6(11):1907-14. PubMed ID: 22005471
    [Abstract] [Full Text] [Related]

  • 34. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ, Aultman R, Carpeño Jde C, Vergnenègre A, Chouaid C, Walzer S, Siebert U.
    Curr Med Res Opin; 2011 Nov 10; 27(11):2193-201. PubMed ID: 21970659
    [Abstract] [Full Text] [Related]

  • 35. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    J Clin Oncol; 2013 Aug 10; 31(23):2895-902. PubMed ID: 23835707
    [Abstract] [Full Text] [Related]

  • 36. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A.
    Cancer; 2012 Nov 15; 118(22):5580-7. PubMed ID: 22544579
    [Abstract] [Full Text] [Related]

  • 37. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C.
    Clin Lung Cancer; 2011 Nov 15; 12(6):407-11. PubMed ID: 21705281
    [Abstract] [Full Text] [Related]

  • 38. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R.
    J Clin Oncol; 2013 Dec 01; 31(34):4349-57. PubMed ID: 24145346
    [Abstract] [Full Text] [Related]

  • 39. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
    Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L.
    Cancer Chemother Pharmacol; 2011 Dec 01; 68(6):1405-12. PubMed ID: 21468755
    [Abstract] [Full Text] [Related]

  • 40. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
    Zhang Q, Cai XW, Zhu ZF, Yu W, Liu Q, Feng W, Xue MC, Fu XL.
    Anticancer Drugs; 2015 Apr 01; 26(4):456-63. PubMed ID: 25646743
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.